Back to Search
HAROLD BURSTEIN, MD PHD
MD PHD
Medical Oncology Physician
NPI: 1285603001IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
150929(MA)
Education
HARVARD MEDICAL SCHOOL
Class of 1994
Research & Publications (20)
Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.
PMID 19675333·N Engl J Med·2009
5-case
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
PMID 18347007·J Clin Oncol·2008
3-trial
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.
PMID 18283035·Ann Oncol·2008
3-trial
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
PMID 19047116·Clin Cancer Res·2008
3-trial
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.
PMID 16969707·Invest New Drugs·2007
3-trial
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
PMID 17614302·Cancer·2007
4-observational
Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
PMID 17550053·J Support Oncol·2007
6-review
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
PMID 16243442·Int J Radiat Oncol Biol Phys·2006
3-trial
Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer.
PMID 17370924·Oncology (Williston Park)·2006
6-review
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.
PMID 16800976·Clin Breast Cancer·2006
5-case
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
PMID 16293865·J Clin Oncol·2005
3-trial
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
PMID 16150805·Ann Oncol·2005
3-trial
Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA.
PMID 16111459·Expert Rev Anticancer Ther·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 44 BINNEY ST, DANA FARBER CANCER INSTITUTE
BOSTON, MA 02115 - Phone
- (617) 632-2624
Quick Facts
- NPI
- 1285603001
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 32
- Publications
- 20
Are you this provider?
Claim Your Profile